Navigation Links
Scientists synthesize unique family of anti-cancer compounds
Date:2/12/2010

New Haven, Conn.Yale University scientists have streamlined the process for synthesizing a family of compounds with the potential to kill cancer and other diseased cells, and have found that they represent a unique category of anti-cancer agents. Their discovery appears in this week's online edition of the Journal of the American Chemical Society.

The team studied a family of compounds known as the kinamycins, which are naturally produced by bacteria during metabolism and are known for their potent toxicity. For years scientists have guessed that a core structure common to the different compounds within the group was responsible for this toxicity. Until now, chemists could not study the core structure because there was no simple way to create it in the laboratory.

Now the Yale team has developed a new method to recreate this structure that allows them to synthesize the kinamycins with much greater efficiency than previously possible. While scientists have produced kinamycins in the laboratory in the past, the Yale team was able to halve the number of steps required to go from simple, easily obtainable precursors to the complete moleculefrom 24 down to 12.

"By shortening the synthesis we can now prepare these molecules in the quantities required for further studies, including animal studies and even clinical trials," said Seth Herzon, assistant professor of chemistry and lead author of the study.

Working with researchers at the Yale School of Medicine and the Yale Chemical Genomics Screening Facility, the team has begun testing several of the compounds against cancer cells, with promising preliminary results. Next, they will work to understand the exact mechanism that makes the compoundswhich are benign on their ownhighly toxic once they penetrate cells.

"The key to success will be whether we can develop selectivitywhether we can kill cancer cells in the presence of non-cancerous tissue," Herzon said. "Based on what we already know about the chemical reactivity of these molecules, I'm optimistic we can do this."

The reactive core of the kinamycins also plays a key role in another compound the team is studying, called lomaiviticin A, which is even more toxic and could prove even more effective in destroying cancer cells. "Lomaiviticin A is the big fish. It's more potent than the kinamycins, but it's also much harder to synthesize," Herzon said.

Both the kinamycins and lomaiviticin A are unique in their toxicity profiles, Herzon said, representing a new category of anti-cancer agents.

"There's no close analogy to draw from to predict how these molecules will behave, which will make it especially interesting to see where this research takes us," Herzon said. "This research involves a lot of exciting chemistry, but it also has real applications in biology and human medicine."


'/>"/>

Contact: Suzanne Taylor Muzzin
suzanne.taylormuzzin@yale.edu
203-432-8555
Yale University
Source:Eurekalert

Related biology news :

1. ASU scientists develop universal DNA reader to advance faster, cheaper sequencing efforts
2. USDA scientists sequence genome of grass that can be a biofuel model crop
3. Prevention is key research goal for premature babies, scientists say
4. Caltech neuroscientists discover brain area responsible for fear of losing money
5. Virus-free technique enables Stanford scientists to easily make stem cells pluripotent
6. Scientists identify first genetic variant linked to biological aging in humans
7. ARS scientists turn to a wild oat to combat crown rust
8. Scientists find quantum mechanics at work in photosynthesis
9. Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug
10. Humble garden pea helps Kew scientists develop cool, noninvasive diagnostic test of seed quality
11. Scripps Research scientists create new way to screen libraries of 10 million or more compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... --  Bridge Patient Portal , an enterprise patient ... Systems , an electronic medical record solutions developer ... a partnership to build an interface between the ... products, including Centricity Practice Solution (CPS), Centricity Business ... integrations will allow healthcare delivery networks using GE ...
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
Breaking Biology News(10 mins):
(Date:6/23/2017)... ... June 23, 2017 , ... ... for all six of their healthcare job boards. As the largest network ... occupational therapists, and biotechnicians, DocCafe.com and the MedJobCafe.com Health Network work to ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... over the allergy specialists DST Diagnostische Systeme & Technologien GmbH, thereby expanding its ... someone who suffers from hay fever, urticaria, asthma, atopic eczema or a food ...
(Date:6/22/2017)... Frederick, MD (PRWEB) , ... June 22, 2017 ... ... software solutions provider, announced the release of Limfinity® version 6.5, a content-packed update ... Limfinity® framework continue to gain a larger and more diverse base of customers ...
(Date:6/20/2017)... June 20, 2017  Kibow Biotech Inc., a pioneer ... the issuance of a new patent covering a unique ... the U.S. Patent and Trademark Office on May 23 ... the Buzz of Bio award in 2014 in ... developing non-drug approaches to chronic disease. Renadylâ„¢, the first ...
Breaking Biology Technology: